Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Sexual Harassment Scandals Hit Novartis and Pfizer's Korea Units

  • Post author:Sam
  • Post published:November 29, 2017
  • Post category:BioPharma

On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September. Source: BioSpace

Continue ReadingSexual Harassment Scandals Hit Novartis and Pfizer's Korea Units

3 Bioeconomy Stocks Investors Should Not Hesitate to Buy

  • Post author:Sam
  • Post published:November 29, 2017
  • Post category:BioPharma

While the words biotech and biopharma are often used interchangeably, they aren't the same thing - not even close, in fact. Source: BioSpace

Continue Reading3 Bioeconomy Stocks Investors Should Not Hesitate to Buy

Boston Scientific Loses $3B on Latest Lotus Valve Delay

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization. Source: BioSpace

Continue ReadingBoston Scientific Loses $3B on Latest Lotus Valve Delay

Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace

Continue ReadingStruggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M

Wavelength Pharma Names Former Sun Exec as New CEO

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

Iftach Seri previously served as Sun Pharmaceutical’s head of API. Source: BioSpace

Continue ReadingWavelength Pharma Names Former Sun Exec as New CEO

Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace

Continue ReadingWhy This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now

Meet the Scientist Who Admits His MS Therapy is 'Largely Ineffective.'

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

What many hope will be the final chapter in an unfortunate saga in multiple sclerosis research appears to have been written by the scientist who started the affair in the…

Continue ReadingMeet the Scientist Who Admits His MS Therapy is 'Largely Ineffective.'

Why This Small SoCal Biotech's Pipeline Makes it Flushed for Growth

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone's interested in fast-growing stocks. Source: BioSpace

Continue ReadingWhy This Small SoCal Biotech's Pipeline Makes it Flushed for Growth

Regeneron Forges Out-of-the-Box R&D Pact With Boston's Decibel Therapeutics

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

Regeneron and Decibel scientists will be working together, shoulder to shoulder, on project teams beginning at the earliest stages of research. Source: BioSpace

Continue ReadingRegeneron Forges Out-of-the-Box R&D Pact With Boston's Decibel Therapeutics

ITUS Pushes CAR-T Program for Solid Tumors, Develops Early Cancer Detection Platform

  • Post author:Sam
  • Post published:November 28, 2017
  • Post category:BioPharma

Tiny ITUS believes it is on track to develop a CAR-T treatment for solid tumors. Source: BioSpace

Continue ReadingITUS Pushes CAR-T Program for Solid Tumors, Develops Early Cancer Detection Platform
  • Go to the previous page
  • 1
  • …
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.